Diabetes drugs including Merck & Co. (MRK)’s Januvia, Bristol-Myers Squibb Co. (BMY)’s Byetta and Novo Nordisk A/S (NOVOB)’s Victoza are being scrutinized by U.S. regulators for a potential link to pancreatic cancer.
The Food and Drug Administration is reviewing unpublished findings by a group of academic researchers that suggest pre- cancerous cellular changes may be associated with Type 2 diabetes drugs called incretin mimetics, according to a statement today from the agency. The findings suggest the class of medicines may be linked to the risk of developing an inflammation of the pancreas tied to cancer and kidney failure that was previously reported in some of the medicines.
